(Q36967173)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Natalie J Carter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

2257-2276

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17927287%20AND%20SRC:MED&resulttype=core&format=json

Diagnosis and management of epithelial ovarian cancer

8 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767150-00009

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Marine natural products as anticancer drugs

1 reference

12 December 2020

Further Insight into the DNA Recognition Mechanism of Trabectedin from the Differential Affinity of Its Demethylated Analogue Ecteinascidin ET729 for the Triplet DNA Binding Site CGA

1 reference

12 December 2020

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

1 reference

12 December 2020

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

1 reference

12 December 2020

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug

1 reference

12 December 2020

1 reference

12 December 2020

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations

1 reference

12 December 2020

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

12 December 2020

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study

1 reference

12 December 2020

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

1 reference

12 December 2020

In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

1 reference

12 December 2020

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

1 reference

12 December 2020

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

1 reference

12 December 2020

Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters

1 reference

12 December 2020

Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.

1 reference

12 December 2020

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Ecteinascidin-743 inhibits activated but not constitutive transcription.

1 reference

12 December 2020

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

1 reference

12 December 2020

Soft-tissue sarcomas in adults

1 reference

12 December 2020

Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

1 reference

12 December 2020

Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma

1 reference

12 December 2020

1 reference

12 December 2020

The management of recurrent ovarian cancer

1 reference

12 December 2020

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

1 reference

12 December 2020

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

12 December 2020

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

12 December 2020

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

12 December 2020

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

12 December 2020

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors

1 reference

12 December 2020

Current management strategies for ovarian cancer

1 reference

12 December 2020

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

1 reference

12 December 2020

Management of platinum-sensitive recurrent ovarian cancer

1 reference

12 December 2020

Principles and practice of intraperitoneal chemotherapy for ovarian cancer

1 reference

12 December 2020

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

12 December 2020

The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.

1 reference

12 December 2020

Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

ET-743: a novel agent with activity in soft-tissue sarcomas

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?

1 reference

12 December 2020

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

12 December 2020

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

1 reference

12 December 2020

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

1 reference

12 December 2020

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

1 reference

12 December 2020

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

12 December 2020

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

12 December 2020

Soft tissue sarcoma: An overview

1 reference

12 December 2020

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

1 reference

12 December 2020

Cancer statistics, 2007

1 reference

12 December 2020

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells

1 reference

12 December 2020